Brain Functions Underlying Visuospatial Attention Deficits in Schizophrenia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01399437
Recruitment Status : Completed
First Posted : July 21, 2011
Last Update Posted : April 5, 2018
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( National Institute on Drug Abuse (NIDA) )

Brief Summary:


- A special brain circuit is important for helping us keeping an eye open for things that are going on around us, even when we are not directly paying attention to them. This circuit seems to work differently in people with schizophrenia than in other people, which may explain specific deficits with broad monitoring observed in people with schizophrenia. Researchers want to compare brain function in people with schizophrenia and healthy volunteers to find out more about how these brain circuits work and affect attention.


- To study how the brain performs broad visual monitoring in people with schizophrenia.


  • Individuals between 18 to 55 years of age who have been diagnosed with schizophrenia.
  • Healthy volunteers between 18 and 55.


  • Participants will be screened with physical and psychological exams. They will have a medical history. Tests for drug and alcohol use will also be done.
  • Participants will have two study visits. The first is a training visit and the second is a scanning visit.
  • At the training visit, participants will practice computer-based tests of focus, memory, and concentration. They will also answer questions about mood, psychiatric symptoms, and smoking habits.
  • At the scanning visit, participants will perform the computer-based tasks that they practiced at the training visit. They will have magnetic resonance imaging while they perform these tasks.

Condition or disease

Detailed Description:

Objective: To test a neural circuit explanation for a visuospatial attention abnormality seen in schizophrenia. Specifically, the aim is to test whether broad monitoring deficits may be based on a disruption of the so-called sentinel function of the default network. Because the default network is modulated by nicotinic compounds, such finding would implicate a possible remediation strategy.<TAB>

Study population: 24 people with schizophrenia, 24 matched healthy control subjects.

Design: A group comparison of attention task performance and associated brain activity as measured by functional Magnetic Resonance Imaging.

Outcome measures: Measures of attention task performance (reaction time, accuracy), BOLD signal within regions of the default network, degree of temporal association of BOLD signal with trial-by-trial reaction time.

Study Type : Observational
Actual Enrollment : 64 participants
Time Perspective: Other
Official Title: Default Network Dysfunction Underlying Visuospatial Attention Deficits in Schizophrenia
Study Start Date : July 3, 2011
Study Completion Date : December 24, 2014

Resource links provided by the National Library of Medicine

Primary Outcome Measures :
  1. Behavioral performance measures on the cognitive tasks (e.g. reaction time, accuracy)
  2. Bold signal, specifically activation of the default network of resting brain function and its association with task performance.

Secondary Outcome Measures :
  1. Secondary outcome measures include ratings and scores on questionnaires and characterization tools.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

All participants:

  1. Age 18 through 55.
  2. Normal or corrected to normal visual acuity (at least 20/80)

    Participants with menat illness:

  3. DSM-IV diagnosis of schizophrenia or schizoaffective disorder
  4. Ability to give written informed consent
  5. Four week of stable pharmacological treatment (same psychiatric medication at same dose or no medication)


All participants:

  1. Presence of ferromagnetic metal objects in the body, implanted electronic devices or any other counter -indication for MRI.
  2. Claustrophobia
  3. Left handed or ambidextrous
  4. History of myocardial infarction or heart failur, which may cause asymptomatic brain lesions
  5. Uncontrolled high blood pressure (resting systolic greater than 150 or diastolic greater than 90 mm Hg)
  6. Neurological conditions likely to impair cognitive function such as stroke, seizures, dementia or organic brian syndrome
  7. Any condition likely to impair cognitive function such as mental retardation or severe pharmacological sedation
  8. Current use of vasodilating beta-blockers (carvedilol, labetalol or nebivolol)
  9. Alcohol or substance abuse or dependence other than nicotine within the last 6 months
  10. Pregnancy, verified by urin pregnancy test for females during screening and on the day of the scan.

    Healthy Controls:

  11. Current psychiatric Axis I disorder or Axis II schizophrenia spectrum disorder, verified by Structured Clinical Interview for DSM-IV (SCID)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01399437

United States, Maryland
Maryland Psychiatric Research Center (MPRC) 55 Wade Avenue
Catonsville, Maryland, United States, 21228
Sponsors and Collaborators
National Institute on Drug Abuse (NIDA)
Principal Investigator: Elliot Stein, Ph.D. National Institute on Drug Abuse (NIDA)

Responsible Party: National Institute on Drug Abuse (NIDA) Identifier: NCT01399437     History of Changes
Other Study ID Numbers: 999911470
First Posted: July 21, 2011    Key Record Dates
Last Update Posted: April 5, 2018
Last Verified: December 24, 2014

Keywords provided by National Institutes of Health Clinical Center (CC) ( National Institute on Drug Abuse (NIDA) ):
Default Network
Spatial Attention
Sentinel Function

Additional relevant MeSH terms:
Attention Deficit Disorder with Hyperactivity
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders
Attention Deficit and Disruptive Behavior Disorders
Neurodevelopmental Disorders